SCHEMBL16611322

SCHEMBL16611322

COc1nccc2c1c(-c1ccc(N3CCOCC3)cc1)nn2-c1c(F)cc(C#N)cc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 5/20 0.43
CCNA2 P20248 3/20 0.42
CDK2 P24941 3/20 0.42
CDK1 P06493 1/20 0.42
CDK4 P11802 1/20 0.42
CCNB1 P14635 1/20 0.42
CCND1 P24385 1/20 0.42
CDK7 P50613 1/20 0.42
CCNH P51946 1/20 0.42
TNIK Q9UKE5 2/20 0.42
LRRK2 Q5S007 1/20 0.39
PRKDC P78527 1/20 0.39
JAK2 O60674 1/20 0.38
MAPK10 P53779 3/20 0.38
MAPK8 P45983 2/20 0.38
GSK3B P49841 1/20 0.37
EGLN2 Q96KS0 1/20 0.37
PIK3CA P42336 1/20 0.37
MTOR P42345 1/20 0.37
KCNH2 Q12809 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610962 0.87 MAP4K1 (0.41) CCNA2CDK2CDK1CDK4CCNB1
SCHEMBL16611763 0.86 CCNA2 (0.43) TBK1CCNA2CDK2CDK1CDK4
SCHEMBL16611300 0.79 KHK (0.46) KCNH2
SCHEMBL16611369 0.79 CCNA2 (0.41) TBK1CCNA2CDK2CDK1CDK4
SCHEMBL16610848 0.75 CCNA2 (0.46) TBK1CCNA2CDK2CDK1CDK4
SCHEMBL16611223 0.75 MTOR (0.39) JAK2MTOR
SCHEMBL16611044 0.74 CYP17A1 (0.40) PIK3CAMTOR
SCHEMBL16610837 0.74 LRRK2 (0.44) CCNA2CDK2CDK1CDK4CCNB1
SCHEMBL16610668 0.71 CKS1B (0.41) LRRK2JAK2
SCHEMBL16610973 0.71 PIK3CG (0.37) CCNA2CDK2CDK1CDK4CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 TBK1 706/4885CCNA2 1165/4885CDK2 302/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 TBK1 706/4885CCNA2 1165/4885CDK2 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.